Tag: FDA accelerated approval

Surrogate Endpoint Validation in Orphan Drug Development

August 26, 2025

Surrogate Endpoint Validation in Orphan Drug Development Validating Surrogate Endpoints in Rare Disease Drug Trials Introduction: Why Surrogate Endpoints Matter in Orphan Drug Development In the world of rare disease clinical research, traditional clinical endpoints—such as survival or long-term functional improvement—can be impractical due to small patient populations, disease heterogeneity, and long progression timelines. This…

Rare and Orphan Disease Trials, Trial Design & Methodology

Designing Single-Arm Studies for Regulatory Acceptance

August 25, 2025

digi

Designing Single-Arm Studies for Regulatory Acceptance Structuring Single-Arm Trials for Rare Disease Regulatory Success Introduction: Why Single-Arm Trials Are Common in Rare Disease Development In rare and ultra-rare disease drug development, the small number of eligible patients often precludes the use of traditional randomized controlled trials (RCTs). In these settings, single-arm studies—where all enrolled patients…

Rare and Orphan Disease Trials, Trial Design & Methodology

First Pediatric Approval in a Rare Neurodegenerative Disease

August 14, 2025

digi

First Pediatric Approval in a Rare Neurodegenerative Disease Breaking Ground: Pediatric Approval in Rare Neurodegenerative Diseases Introduction: The Urgent Need for Pediatric Approvals Neurodegenerative diseases in children represent some of the most devastating rare disorders. Conditions such as spinal muscular atrophy (SMA), Batten disease, and certain leukodystrophies often present in infancy or early childhood, leading…

Case Studies & Breakthroughs, Rare and Orphan Disease Trials

First-in-Class Treatment Approval for Rare Cardiac Disorder

August 12, 2025

digi

First-in-Class Treatment Approval for Rare Cardiac Disorder How First-in-Class Therapies Achieve Approval in Rare Cardiac Disorders Introduction: Unmet Needs in Rare Cardiac Disorders Rare cardiac disorders, such as restrictive cardiomyopathy or inherited arrhythmia syndromes, often lack established treatment options due to their low prevalence and highly variable clinical presentation. These conditions frequently lead to early…

Case Studies & Breakthroughs, Rare and Orphan Disease Trials

Conditional Approval Pathways for Unmet Needs

August 6, 2025

digi

Conditional Approval Pathways for Unmet Needs How Conditional Approvals Accelerate Therapies for Unmet Rare Disease Needs Understanding the Concept of Conditional Approval In the context of rare and life-threatening diseases, traditional drug approval processes—requiring full clinical trial data—may delay patient access to critical therapies. Regulatory agencies such as the European Medicines Agency (EMA) and the…

Rare and Orphan Disease Trials, Regulatory Incentives